Randomized controlled trialHumanClinical Trial, Phase III

Tirzepatide Once Weekly for the Treatment of Obesity

The New England journal of medicine, 2022 Jul 21. Jastreboff AM, Aronne LJ, Ahmad NN and 9 others.

Study type

Randomized controlled trial · Clinical Trial, Phase III

Subjects

Human participants (PubMed MeSH: Humans)

Journal

The New England journal of medicine

Published

2022 Jul 21

PubMed

PMID 35658024 ↗

DOI

10.1056/NEJMoa2206038 ↗

Where PepCue cites this

This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.

Tirzepatide →peptides for weight loss proven vs hype →semaglutide vs tirzepatide vs retatrutide →

Indexed under

MeSH terms assigned by the National Library of Medicine.

AdultAnti-Obesity AgentsDose-Response Relationship, DrugDouble-Blind MethodGastric Inhibitory PolypeptideGlucagon-Like PeptidesHumansInjections, SubcutaneousObesityTreatment OutcomeWeight LossTirzepatide

Other papers on Tirzepatide

Randomized controlled trial · 2024

Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity

Randomized controlled trial · 2021

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page